更正：在真实世界和试验环境中，阿哌沙班与其他抗凝剂相比在房颤患者中的成本效益。
Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.
作者信息
de Jong Lisa A, Groeneveld Jessie, Stevanovic Jelena, Rila Harrie, Tieleman Robert G, Huisman Menno V, Postma Maarten J, van Hulst Marinus
出版信息
PLoS One. 2022 Mar 31;17(3):e0266625. doi: 10.1371/journal.pone.0266625. eCollection 2022.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0222658.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.pone.0222658。]
Zotero 插件